A recent published work by Proud’s group showed that eEF2K can promote PD-L1 expression in prostate and lung cancer cells.39 Emerging data suggest that patients whose tumors overexpress PD-L1 have better clinical outcomes with anti-PD-1 therapy. The gene discussed is PDCD1; the disease is lung cancer.